ProStrakan Group plc - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 93

ProStrakan Group plc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “ProStrakan Group plc - Product Pipeline Review - H2 2011” provides data on the ProStrakan Group plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ProStrakan Group plc’s corporate website, SEC filings, investor presentations and featured press releases, both from ProStrakan Group plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ProStrakan Group plc - Brief ProStrakan Group plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ProStrakan Group plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ProStrakan Group plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ProStrakan Group plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ProStrakan Group plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ProStrakan Group plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ProStrakan Group plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ProStrakan Group plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ProStrakan Group plc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of ProStrakan Group plc; ProStrakan Group plc - Key Therapeutics; ProStrakan Group plc - Pipeline Overview and Promising Molecules; ProStrakan Group plc - News; ProStrakan Group plc - Latest Updates; ProStrakan Group plc - Pipeline; ProStrakan Group plc - Discontinued/Dormant Projects

List of Tables
List of Figures
ProStrakan Group plc Snapshot
ProStrakan Group plc Overview
Key Information
Key Facts
ProStrakan Group plc – Research and Development Overview
Key Therapeutic Areas
ProStrakan Group plc – Pipeline Review
Pipeline Products by Stage of Development
ProStrakan Group plc – Pipeline Products Glance
ProStrakan Group plc – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
ProStrakan Group plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
ProStrakan Group plc – Drug Profiles
Sancuso
Product Description
Mechanism of Action
R&D Progress
Testosterone-Glucoside
Product Description
Mechanism of Action
R&D Progress
ProStrakan Group plc – Pipeline Analysis
ProStrakan Group plc – Pipeline Products by Therapeutic Class
ProStrakan Group plc - Pipeline Products By Target
ProStrakan Group plc – Pipeline Products by Route of Administration
ProStrakan Group plc – Pipeline Products by Molecule Type
ProStrakan Group plc – Recent Pipeline Updates
ProStrakan Group plc - Dormant Projects
ProStrakan Group plc – Company Statement
ProStrakan Group plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 27, 2004: Strakan Initiates Phase I Trial Of Testosterone-Glucoside
Dec 26, 2004: FDA Issues Not Approvable Letter For Cellegesic - Cellegy Pharmaceuticals
Jun 25, 2009: ProStrakan Announces Publication of Notice of Allowance for Sancuso US Patent
May 23, 2008: ProStrakan and JapanBridge Partner to Develop Sancuso in Japan, China & Parts of South East Asia
Apr 23, 2008: FDA Moves Sancuso PDUFA Date to mid-June
Dec 22, 2008: ProStrakan Announces Outlicensing of Abstral and Sancuso in Canada
Jun 22, 2011: ProStrakan Receives FDA Approval For Rectiv For Treatment Of Moderate To Severe Pain Associated With Chronic Anal Fissures
Oct 21, 2009: ProStrakan Announces FDA Acceptance of US Submission of Cellegesic (Nitroglycerin) 0.4% Ointment
Aug 20, 2007: ProStrakan Announces Commencement Of Recruitment In Pivotal US Trials For Cellegesic (Rectogesic)
Jul 18, 2008: Sancuso - PDUFA Action Date Market Update
Sep 15, 2008: ProStrakan Receives US FDA Approval for Sancuso
Aug 13, 2007: ProStrakan Announces LG Life Sciences as South Korean Partner for Sancuso
Jan 12, 2006: Adcal D3 takes market lead
Jul 11, 2008: New PDUFA Action Date for Sancuso
Jul 11, 2006: FDA Issusses Approvable Letter To Cellegy Pharmaceuticals For Cellegesic
Feb 09, 2009: ProStrakan Announces Further Outlicensing Deals in Globalisation of Sancuso
May 05, 2009: ProStrakan Announces US Submission Of Fortigel (Testosterone) 2% Gel
Dec 03, 2007: ProStrakan Receives Approval for Adcal-D3 Dissolve
Nov 03, 2008: ProStrakan Launches Sancuso in US
Jun 02, 2008: Update on Sancuso US Regulatory Review Status
Apr 01, 2010: ProStrakan Receives Complete Response Letter For Rectogesic From FDA
Financial Deals Landscape
ProStrakan Group plc, Deals Summary
ProStrakan Group plc, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
ProStrakan Acquires Expanded Rights To Rectogesic and Tostran From Cellegy Pharmaceuticals
Private Equity
ProStrakan Raise $39.76 Million
Partnerships
Endo Pharmaceuticals Signs Licensing Agreement With ProStrakan Group
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics
ProStrakan Forms Partnership With NovaQuest
ProStrakan Signs An Agreement With LG Life Sciences
ProStrakan Forms Joint Venture With Orexo
ProStrakan Enters Into Distribution Agreement With Gedeon Richter
TiGenix Enters Into Co-Development Agreement With ProStrakan
Merger
Strakan Merges With Proskelia
Licensing Agreements
Abeille Pharmaceuticals Enters Into Licensing Agreement With Prostrakan
ProStrakan Enters Into Licensing Agreement with Genus Pharmaceuticals
ProStrakan Enters Into Sub-Licensing Agreement With Cantabria Farmaceutica
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group
Paladin Labs Enters Into Licensing Agreement With ProStrakan
Bayer Schering Signs License Agreement With ProStrakan Group
ProStrakan Enters Into License Agreement With NewBridge
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Enters Into Licensing Agreement With JapanBridge
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring
ProStrakan Enters Into Licensing Agreement With Novartis
ProStrakan Enters Into Licensing Agreement With Amgen
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals
Cellegy Pharmaceuticals Amends License Agreement With ProStrakan For Tostrex
ProStrakan Enters Into Licensing Agreement With Orexo
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic
ProStrakan Enters Into Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic
Clinuvel Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals
Cellegy Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals For Tostrex
Equity Offering
ProStrakan Completes Private Placement Of $20.8 Million
Asset Transactions
Crawford Healthcare Acquires Zindaclin From ULURU And Strakan
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare
Acquisition
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan
Norgine Acquires 12.61% Stake In ProStrakan
MDY Healthcare Acquires Minority Stake In ProStrakan Group
ProStrakan Group Sells ProSkelia To Galapagos
ProStrakan Acquires APS Pharma
ProStrakan Acquires Elfar
Prostrakan Acquires OTL Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
ProStrakan Group plc – Pipeline by Therapy Area and Indication, H2 2011
ProStrakan Group plc – Pipeline by Stage of Development, H2 2011
ProStrakan Group plc – Filed, H2 2011
ProStrakan Group plc – Phase III, H2 2011
ProStrakan Group plc - Phase II, H2 2011
ProStrakan Group plc - Pipeline By Therapeutic Class, H2 2011
ProStrakan Group plc - Pipeline By Target, H2 2011
ProStrakan Group plc – Pipeline By Route of Administration, H2 2011
ProStrakan Group plc – Pipeline By Molecule Type, H2 2011
ProStrakan Group plc – Recent Pipeline Updates, H2 2011
ProStrakan Group plc - Dormant Developmental Projects, 2010
ProStrakan Group plc, Other Locations
ProStrakan Group plc, Subsidiaries
ProStrakan Group plc, Deals Summary
ProStrakan Acquires Expanded Rights To Rectogesic and Tostran From Cellegy Pharmaceuticals
ProStrakan Raise $39.76 Million
Endo Pharmaceuticals Signs Licensing Agreement With ProStrakan Group
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics
ProStrakan Forms Partnership With NovaQuest
ProStrakan Signs An Agreement With LG Life Sciences
ProStrakan Forms Joint Venture With Orexo
ProStrakan Enters Into Distribution Agreement With Gedeon Richter
TiGenix Enters Into Co-Development Agreement With ProStrakan
Strakan Merges With Proskelia
Abeille Pharmaceuticals Enters Into Licensing Agreement With Prostrakan
ProStrakan Enters Into Licensing Agreement with Genus Pharmaceuticals
ProStrakan Enters Into Sub-Licensing Agreement With Cantabria Farmaceutica
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group
Paladin Labs Enters Into Licensing Agreement With ProStrakan
Bayer Schering Signs License Agreement With ProStrakan Group
ProStrakan Enters Into License Agreement With NewBridge
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Enters Into Licensing Agreement With JapanBridge
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring
ProStrakan Enters Into Licensing Agreement With Novartis
ProStrakan Enters Into Licensing Agreement With Amgen
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals
Cellegy Pharmaceuticals Amends License Agreement With ProStrakan For Tostrex
ProStrakan Enters Into Licensing Agreement With Orexo
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic
ProStrakan Enters Into Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic
Clinuvel Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals
Cellegy Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals For Tostrex
ProStrakan Completes Private Placement Of $20.8 Million
Crawford Healthcare Acquires Zindaclin From ULURU And Strakan
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan
Norgine Acquires 12.61% Stake In ProStrakan
MDY Healthcare Acquires Minority Stake In ProStrakan Group
ProStrakan Group Sells ProSkelia To Galapagos
ProStrakan Acquires APS Pharma
ProStrakan Acquires Elfar
Prostrakan Acquires OTL Pharma

List of Figures
ProStrakan Group plc – Pipeline by Therapy Area and Indication, H2 2011
ProStrakan Group plc – Pipeline by Stage of Development, H2 2011
ProStrakan Group plc – Pipeline By Therapeutic Class, H2 2011
ProStrakan Group plc - Pipeline By Target, H2 2011
ProStrakan Group plc – Pipeline By Route of Administration, H2 2011
ProStrakan Group plc – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile